Table 2.
Result of network meta-analysis and pairwise meta-analysis for the incidence of cancer (A), cardiovascular disease (B), hip fracture (C), and death (D).
| A. Cancer | ||||||
| SERM | 0.65 (0.40, 0.90) | |||||
| 0.62 (0.43, 0.91) | mAb | 1.09 (0.58, 1.61) | 1.03 (0.76, 1.29) | |||
| 0.64 (0.37, 1.10) | 1.03 (0.66, 1.59) | BP | 1.12 (0.45, 1.79) | |||
| 0.65 (0.48, 0.88) | 1.04 (0.83, 1.31) | 1.01 (0.65, 1.58) | Placebo | |||
| B. Cardiovascular Disease | ||||||
| SERM | 1.03 (0.79, 1.26) | |||||
| 0.92 (0.63, 1.35) | mAb | 1.05 (0.86, 1.24) | ||||
| 0.97 (0.56, 1.68) | 1.06 (0.62, 1.79) | BP | 1.00 (0.56, 1.43) | |||
| 0.97 (0.73, 1.29) | 1.05 (0.82, 1.35) | 1.00 (0.63, 1.59) | Placebo | |||
| C. Hip Fracture | ||||||
| Fluoride | 1.04 (−0.34, 2.41) | |||||
| 0.99 (0.20, 4.99) | Calcitonin | 0.75 (−0.25, 1.75) | ||||
| 1.86 (0.36, 9.63) | 1.87 (0.44, 7.98) | PTH | 0.40 (−1.25, 2.04) | 0.75 (−0.75, 2.25) | ||
| 0.78 (0.20, 3.01) | 0.79 (0.26, 2.37) | 0.42 (0.13, 1.33) | SERM | 0.95 (0.50, 1.40) | ||
| 1.24 (0.32, 4.82) | 1.25 (0.41, 3.80) | 0.67 (0.21, 2.13) | 1.58 (0.81, 3.08) | mAb | 0.60 (0.11, 1.09) | |
| 1.28 (0.34, 4.74) | 1.29 (0.45, 3.70) | 0.69 (0.24, 1.99) | 1.63 (0.93, 2.86) | 1.03 (0.57, 1.87) | BP | 0.58 (0.23, 0.92) |
| 0.75 (0.21, 2.65) | 0.75 (0.28, 2.05) | 0.40 (0.14, 1.15) | 0.95 (0.61, 1.50) | 0.60 (0.37, 0.98) | 0.58 (0.42, 0.82) | Placebo |
| D. Death | ||||||
| PTH | 2.17 (1.27, 3.07) | 0.60 (−0.83, 2.03) | ||||
| 1.18 (0.46, 3.05) | SERM | 1.23 (0.79, 1.67) | ||||
| 1.75 (0.65, 4.71) | 1.49 (0.86, 2.58) | mAb | 0.78 (0.50, 1.05) | |||
| 1.49 (0.64, 3.45) | 1.26 (0.74, 2.14) | 0.85 (0.47, 1.53) | BP | 1.02 (0.65, 1.38) | ||
| 1.40 (0.58, 3.39) | 1.19 (0.83, 1.69) | 0.80 (0.52, 1.21) | 0.94 (0.63, 1.40) | Placebo | ||
Results of network meta-analysis (mixed comparison; lower-left portion) and pairwise meta-analysis (direct comparison; upper-right portion) for the incidence of death in postmenopausal women with osteoporosis. The outcomes are expressed as odds ratio (OR) (95% confidence intervals). For the pairwise meta-analyses, OR of less than 1 indicate that the treatment specified in the row had fewer incidences than that specified in the column. For the network meta-analysis (NMA), OR of less than 1 indicate that the treatment specified in the column had fewer incidences than that specified in the row. Abbreviation: BP, bisphosphonate; mAb, monoclonal antibody; PTH, parathyroid hormone; SERM, selective estrogen receptor modulator.